{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T01:00:40Z","timestamp":1788397240340,"version":"build-2803163510"},"reference-count":105,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100010265","name":"Guizhou Medical University","doi-asserted-by":"publisher","award":["gyfybsky-2024-09"],"award-info":[{"award-number":["gyfybsky-2024-09"]}],"id":[{"id":"10.13039\/501100010265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ctrv.2025.102970","type":"journal-article","created":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T01:29:51Z","timestamp":1748136591000},"page":"102970","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Ovarian escape in premenopausal breast cancer: Challenges and strategies for optimizing hormone suppression"],"prefix":"10.1016","volume":"139","author":[{"given":"Lan","family":"Luo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonglin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senguo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2914-1091","authenticated-orcid":false,"given":"Shu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ctrv.2025.102970_b0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ctrv.2025.102970_b0010","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.breast.2022.08.010","article-title":"Current and future burden of breast cancer: Global statistics for 2020 and 2040","volume":"66","author":"Arnold","year":"2022","journal-title":"Breast"},{"issue":"Suppl 2","key":"10.1016\/j.ctrv.2025.102970_b0015","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/j.breast.2015.07.036","article-title":"Management of breast cancer in very young women","volume":"24","author":"Rosenberg","year":"2015","journal-title":"Breast"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102970_b0020","doi-asserted-by":"crossref","first-page":"e516","DOI":"10.3747\/co.27.6751","article-title":"A pan-Canadian prospective study of young women with breast cancer: the rationale and protocol design for the RUBY study","volume":"27","author":"Quan","year":"2020","journal-title":"Curr Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102970_b0025","doi-asserted-by":"crossref","first-page":"5488","DOI":"10.1038\/s41467-020-19291-x","article-title":"Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer","volume":"11","author":"Lee","year":"2020","journal-title":"Nat Commun"},{"issue":"10074","key":"10.1016\/j.ctrv.2025.102970_b0030","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Breast cancer","volume":"389","author":"Harbeck","year":"2017","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.ctrv.2025.102970_b0035","doi-asserted-by":"crossref","first-page":"2557","DOI":"10.1056\/NEJMra1307118","article-title":"Systemic therapy for estrogen receptor-positive, HER2-negative breast cancer","volume":"383","author":"Burstein","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102970_b0040","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1803164","article-title":"Tailoring adjuvant endocrine therapy for premenopausal breast cancer","volume":"379","author":"Francis","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.102970_b0045","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2021.03.017","article-title":"Five-year changes in ovarian function restoration in premenopausal patients with breast cancer taking tamoxifen after chemotherapy: An ASTRRA study report","volume":"151","author":"Kim","year":"2021","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102970_b0050","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1200\/JCO.22.01065","article-title":"Adjuvant endocrine therapy in premenopausal breast cancer: 12-year results from SOFT","volume":"41","author":"Francis","year":"2023","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102970_b0055","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1200\/JCO.22.01064","article-title":"Adjuvant exemestane with ovarian suppression in premenopausal breast cancer: long-term follow-up of the combined TEXT and SOFT trials","volume":"41","author":"Pagani","year":"2023","journal-title":"J Clin Oncol"},{"issue":"35","key":"10.1016\/j.ctrv.2025.102970_b0060","doi-asserted-by":"crossref","first-page":"4071","DOI":"10.1200\/JCO.21.02844","article-title":"Twenty-year benefit from adjuvant goserelin and tamoxifen in premenopausal patients with breast cancer in a controlled randomized clinical trial","volume":"40","author":"Johansson","year":"2022","journal-title":"J Clin Oncol"},{"issue":"14","key":"10.1016\/j.ctrv.2025.102970_b0065","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1200\/JCO.2015.65.9573","article-title":"Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline update on ovarian suppression","volume":"34","author":"Burstein","year":"2016","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102970_b0070","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s11864-024-01190-8","article-title":"Ovarian suppression: early menopause and late effects","volume":"25","author":"Molinelli","year":"2024","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.ctrv.2025.102970_b0075","doi-asserted-by":"crossref","unstructured":"Thomssen C, Balic M, Harbeck N, et al. St. Gallen\/Vienna 2021: A brief summary of the consensus discussion on customizing therapies for women with early breast cancer. Breast Care (Basel) 2021;16(2):135-143. doi: 10.1159\/000516114.","DOI":"10.1159\/000516114"},{"issue":"9574","key":"10.1016\/j.ctrv.2025.102970_b0080","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1016\/S0140-6736(07)60778-8","article-title":"Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials","volume":"369","author":"Cuzick","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2025.102970_b0085","article-title":"Ovarian suppression for adjuvant treatment of hormone receptor-positive early breast cancer","volume":"3(3)","author":"Bui","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"issue":"Supplement","key":"10.1016\/j.ctrv.2025.102970_b0090","doi-asserted-by":"crossref","first-page":"S142","DOI":"10.4103\/ijc.IJC_65_21","article-title":"Gonadotropin-releasing hormone agonists in prostate cancer: A comparative review of efficacy and safety","volume":"59","author":"Raja","year":"2022","journal-title":"Indian J Cancer"},{"key":"10.1016\/j.ctrv.2025.102970_b0095","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2023.1143261","article-title":"Conventional and new proposals of GnRH therapy for ovarian, breast, and prostatic cancers","volume":"14","author":"Garrido","year":"2023","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.ctrv.2025.102970_b0100","article-title":"LHRH agonists for adjuvant therapy of early breast cancer in premenopausal women","volume":"2009(4)","author":"Goel","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102970_b0105","doi-asserted-by":"crossref","first-page":"355","DOI":"10.6004\/jnccn.2016.0038","article-title":"Fertility preservation in patients with breast cancer: necessity, methods, and safety","volume":"14","author":"Waks","year":"2016","journal-title":"J Natl Compr Canc Netw"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102970_b0110","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10549-023-06877-4","article-title":"Comparison of goserelin and leuprorelin for ovarian protection during chemotherapy in young patients with breast cancer","volume":"198","author":"Kim","year":"2023","journal-title":"Breast Cancer Res Treat"},{"issue":"9472","key":"10.1016\/j.ctrv.2025.102970_b0115","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","article-title":"Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials","volume":"365","author":"Ebctcg","year":"2005","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.ctrv.2025.102970_b0120","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1200\/JCO.18.01967","article-title":"Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT","volume":"38","author":"Pagani","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102970_b0125","article-title":"Clinical management of ovarian function suppression in premenopausal women with breast cancer: a survey of members of ASCO","author":"Kelly","year":"2024","journal-title":"JCO Oncol Pract"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102970_b0130","doi-asserted-by":"crossref","first-page":"331","DOI":"10.6004\/jnccn.2024.0035","article-title":"Breast cancer, Version 3.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Gradishar","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102970_b0135","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s002800050924","article-title":"Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients","volume":"43","author":"Boccardo","year":"1999","journal-title":"Cancer Chemother Pharmacol"},{"issue":"18","key":"10.1016\/j.ctrv.2025.102970_b0140","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.2165\/00003495-200565180-00011","article-title":"Goserelin: a review of its use in the treatment of early breast cancer in premenopausal and perimenopausal women","volume":"65","author":"Cheer","year":"2005","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102970_b0145","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.31557\/APJCP.2019.20.5.1475","article-title":"Clinical studies investigating the use of leuprorelin in breast cancer patients from Asia","volume":"20","author":"Han","year":"2019","journal-title":"Asian Pac J Cancer Prev"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102970_b0150","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s12282-015-0637-4","article-title":"Phase 3, open-label, randomized study comparing 3-monthly with monthly goserelin in pre-menopausal women with estrogen receptor-positive advanced breast cancer","volume":"23","author":"Noguchi","year":"2016","journal-title":"Breast Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102970_b0155","doi-asserted-by":"crossref","first-page":"e939","DOI":"10.1016\/j.clbc.2018.04.005","article-title":"Efficacy of Different Leuprolide Administration Schedules in Premenopausal Breast Cancer: ARetrospective Review","volume":"18","author":"Kendzierski","year":"2018","journal-title":"Clin Breast Cancer"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102970_b0160","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10549-010-1332-y","article-title":"Monthly versus 3-monthly goserelin acetate treatment in pre-menopausal patients with estrogen receptor-positive early breast cancer","volume":"126","author":"Masuda","year":"2011","journal-title":"Breast Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102970_b0165","doi-asserted-by":"crossref","first-page":"553","DOI":"10.4048\/jbc.2020.23.e57","article-title":"Change in estradiol levels among premenopausal patients with breast cancer treated using leuprolide acetate 11.25 milligrams 3-month depot and tamoxifen","volume":"23","author":"Lee","year":"2020","journal-title":"J Breast Cancer"},{"issue":"10","key":"10.1016\/j.ctrv.2025.102970_b0170","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/jnci\/djae115","article-title":"Different dosage forms of GnRHa with endocrine therapy in premenopausal hormone Receptor-Positive breast cancer","volume":"116","author":"Lin","year":"2024","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2025.102970_b0175","article-title":"Effectiveness of a 6-Month 22.5-mg Leuprolide Acetate Depot Formulation With Tamoxifen for Postoperative Premenopausal Estrogen Suppression in Hormone Receptor-Positive Breast Cancer","volume":"11","author":"Wu","year":"2021","journal-title":"Front Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2025.102970_b0180","doi-asserted-by":"crossref","first-page":"4209","DOI":"10.3390\/curroncol31080314","article-title":"An Overview of Long-Acting GnRH Agonists in Premenopausal Breast Cancer Patients: Survivorship Challenges and Management","volume":"31","author":"LeVasseur","year":"2024","journal-title":"Curr Oncol"},{"issue":"11","key":"10.1016\/j.ctrv.2025.102970_b0185","article-title":"Goserelin Ovarian Ablation Failure in Premenopausal Women With Breast Cancer","volume":"13","author":"Gupta","year":"2021","journal-title":"Cureus"},{"issue":"16","key":"10.1016\/j.ctrv.2025.102970_b0190","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1200\/JCO.2005.05.3694","article-title":"Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102970_b0195","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1006\/gyno.1999.5641","article-title":"Failure of goserelin ovarian ablation in premenopausal women with breast cancer: two case reports","volume":"76","author":"Jim\u00e9nez-Gordo","year":"2000","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102970_b0200","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1075-122X.2006.00318.x","article-title":"Aromatase inhibitors in premenopausal women: the need for proper contraceptive counseling","volume":"12","author":"Vandenput","year":"2006","journal-title":"Breast J"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102970_b0205","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1007\/s12282-013-0469-z","article-title":"A case of delivery of healthy infant in breast cancer patient incidentally treated with goserelin acetate and tamoxifen during pregnancy","volume":"23","author":"Ishizuka","year":"2016","journal-title":"Breast Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102970_b0210","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jogoh.2018.03.002","article-title":"Ovarian suppression failure during GnRH agonist treatment: A report of three breast cancer patients","volume":"47","author":"de Ciantis","year":"2018","journal-title":"J Gynecol Obstet Hum Reprod"},{"issue":"14","key":"10.1016\/j.ctrv.2025.102970_b0215","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1200\/JCO.2015.65.3493","article-title":"Is estradiol monitoring necessary in women receiving ovarian suppression for breast cancer?","volume":"34","author":"Papakonstantinou","year":"2016","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102970_b0220","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13058-020-01344-0","article-title":"Fibroblasts direct differentiation of human breast epithelial progenitors","volume":"22","author":"Morsing","year":"2020","journal-title":"Breast Cancer Res"},{"issue":"14","key":"10.1016\/j.ctrv.2025.102970_b0230","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1200\/JCO.2015.61.2259","article-title":"Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): the SOFT-EST substudy","volume":"34","author":"Bellet","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102970_b0235","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10549-024-07323-9","article-title":"Effectiveness of gonadotropin-releasing hormone agonists for ovarian function suppression in premenopausal patients with hormone receptor-positive breast cancer: a retrospective single-center real-world study","volume":"206","author":"Chen","year":"2024","journal-title":"Breast Cancer Res Treat"},{"issue":"18","key":"10.1016\/j.ctrv.2025.102970_b0240","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1200\/JCO.2006.08.8534","article-title":"Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study","volume":"25","author":"Schmid","year":"2007","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102970_b0245","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1007\/s12032-012-0354-1","article-title":"Two different formulations with equivalent effect? Comparison of serum estradiol suppression with monthly goserelin and trimonthly leuprolide in breast cancer patients","volume":"30","author":"Aydiner","year":"2013","journal-title":"Med Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102970_b0250","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.4143\/crt.2016.463","article-title":"Bilateral salpingo-oophorectomy compared to gonadotropin-releasing hormone agonists in premenopausal hormone receptor-positive metastatic breast cancer patients treated with aromatase inhibitors","volume":"49","author":"Suh","year":"2017","journal-title":"Cancer Res Treat"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102970_b0255","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1200\/JCO.18.00296","article-title":"Neoadjuvant Degarelix Versus Triptorelin in Premenopausal Patients Who Receive Letrozole for Locally Advanced Endocrine-Responsive Breast Cancer: A Randomized Phase II Trial","volume":"37","author":"Dellapasqua","year":"2019","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102970_b0260","doi-asserted-by":"crossref","first-page":"e936","DOI":"10.1002\/onco.13722","article-title":"Measuring ovarian escape in premenopausal estrogen receptor-positive breast cancer patients on ovarian suppression therapy","volume":"26","author":"Burns","year":"2021","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102970_b0265","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.clbc.2022.09.007","article-title":"Measurable serum estradiol and estrone in women 36-56 years during adjuvant treatment with aromatase inhibitors for a hormone receptor-positive breast cancer. case studies and cross-sectional study using an ultra-sensitive LC-MS\/MS-method","volume":"23","author":"Van Houdt","year":"2023","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102970_b0270","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.clbc.2023.03.009","article-title":"Ovarian function suppression in premenopausal women with concurrent endocrine therapy use","volume":"23","author":"Fleege","year":"2023","journal-title":"Clin Breast Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102970_b0275","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/s41523-024-00680-0","article-title":"Estrogen levels in young women with hormone receptor-positive breast cancer on ovarian function suppression therapy","volume":"10","author":"Tesch","year":"2024","journal-title":"NPJ Breast Cancer"},{"issue":"3 Pt 1","key":"10.1016\/j.ctrv.2025.102970_b0280","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1016\/S0022-5347(05)67290-4","article-title":"Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm","volume":"164","author":"Oefelein","year":"2000","journal-title":"J Urol"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102970_b0285","doi-asserted-by":"crossref","first-page":"4201","DOI":"10.3390\/ijerph19074201","article-title":"Sex-specific differences in lower body fat distribution and association with physical performance among healthy community-dwelling older adults: a pilot study","volume":"19","author":"Kim","year":"2022","journal-title":"Int J Environ Res Public Health"},{"issue":"19","key":"10.1016\/j.ctrv.2025.102970_b0290","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1200\/JCO.2010.33.2585","article-title":"Impact of body mass index on the efficacy of endocrine therapy in premenopausal patients with breast cancer: an analysis of the prospective ABCSG-12 trial","volume":"29","author":"Pfeiler","year":"2011","journal-title":"J Clin Oncol"},{"issue":"36","key":"10.1016\/j.ctrv.2025.102970_b0295","doi-asserted-by":"crossref","first-page":"5769","DOI":"10.1200\/JCO.2006.07.2793","article-title":"Amenorrhea in premenopausal women after adjuvant chemotherapy for breast cancer","volume":"24","author":"Walshe","year":"2006","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102970_b0300","doi-asserted-by":"crossref","first-page":"11372","DOI":"10.18632\/oncotarget.14532","article-title":"The correlation of age with chemotherapy-induced ovarian function failure in breast cancer patients","volume":"8","author":"Vriens","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102970_b0305","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13287-022-02759-6","article-title":"Important role of the SDF-1\/CXCR4 axis in the homing of systemically transplanted human amnion-derived mesenchymal stem cells (hAD-MSCs) to ovaries in rats with chemotherapy-induced premature ovarian insufficiency (POI)","volume":"13","author":"Ling","year":"2022","journal-title":"Stem Cell Res Ther"},{"issue":"12","key":"10.1016\/j.ctrv.2025.102970_b0310","doi-asserted-by":"crossref","first-page":"2986","DOI":"10.1158\/1078-0432.CCR-19-3091","article-title":"Anastrozole has an association between degree of estrogen suppression and outcomes in early breast cancer and is a ligand for estrogen receptor \u03b1","volume":"26","author":"Ingle","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102970_b0315","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s10549-006-9401-y","article-title":"Identifying menopause in breast cancer patients: considerations and implications","volume":"104","author":"Clemons","year":"2007","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102970_b0320","first-page":"238","article-title":"Menopausal criteria after adjuvant therapy for premenopausal women with breast cancer in China and consensus on clinical application of aromatase","volume":"22","author":"CACA-CBCS","year":"2012","journal-title":"China Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102970_b0325","doi-asserted-by":"crossref","first-page":"293","DOI":"10.4103\/ijc.IJC_697_18","article-title":"Revisiting adjuvant ovarian suppression in premenopausal breast cancer patients","volume":"56","author":"Abbas","year":"2019","journal-title":"Indian J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102970_b0330","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41523-024-00614-w","article-title":"Selection of appropriate biomarkers to monitor effectiveness of ovarian function suppression in pre-menopausal patients with ER+ breast cancer","volume":"10","author":"McCann","year":"2024","journal-title":"npj Breast Cancer"},{"issue":"16","key":"10.1016\/j.ctrv.2025.102970_b0335","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1200\/JCO.2005.05.3694","article-title":"Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines","volume":"24","author":"Smith","year":"2006","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2025.102970_b0340","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2025.102970_b0345","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.talanta.2015.12.062","article-title":"Derivatization of estrogens enhances specificity and sensitivity of analysis of human plasma and serum by liquid chromatography tandem mass spectrometry","volume":"151","author":"Faqehi","year":"2016","journal-title":"Talanta"},{"key":"10.1016\/j.ctrv.2025.102970_b0350","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/8716160","article-title":"Determining the optimal cut-off values of serum E2 and FSH for evaluating the menopausal status of breast cancer patients in a southern Chinese population","volume":"2022","author":"Yang","year":"2022","journal-title":"Dis Markers"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102970_b0355","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1007\/s10549-021-06168-w","article-title":"Monitoring serum estradiol levels in breast cancer patients during extended adjuvant letrozole treatment after five years of tamoxifen: a prospective trial","volume":"187","author":"Faltinov\u00e1","year":"2021","journal-title":"Breast Cancer Res Treat"},{"issue":"17","key":"10.1016\/j.ctrv.2025.102970_b0360","doi-asserted-by":"crossref","first-page":"10665","DOI":"10.1021\/acsami.5b10996","article-title":"Highly sensitive detection of hormone estradiol E2 using surface-enhanced Raman scattering based immunoassays for the clinical diagnosis of precocious puberty","volume":"8","author":"Wang","year":"2016","journal-title":"ACS Appl Mater Interf"},{"key":"10.1016\/j.ctrv.2025.102970_b0365","article-title":"Fulvestrant may falsely increase 17\u03b2-estradiol levels in immunoassays: a case report of a 57-year-old postmenopausal patient with recurrent estrogen receptor-positive breast cancer","volume":"12","author":"Ding","year":"2022","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.102970_b0370","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1038\/s41416-019-0378-9","article-title":"Oestradiol measurement during fulvestrant treatment for breast cancer","volume":"120","author":"Owen","year":"2019","journal-title":"Br J Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102970_b0375","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10549-024-07439-y","article-title":"Monitoring of estradiol levels in premenopausal women receiving adjuvant abemaciclib and ovarian function suppression","volume":"207","author":"Kessler","year":"2024","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2025.102970_b0380","article-title":"Discrepancies in estradiol levels in a premenopausal woman receiving abemaciclib despite ovarian function suppression and bilateral salpingo-oophorectomy","volume":"9","author":"Kessler","year":"2023","journal-title":"Curr Probl Cancer Case Rep"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102970_b0385","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1177\/0004563216674031","article-title":"Falsely elevated serum oestradiol due to exemestane therapy","volume":"54","author":"Mandic","year":"2017","journal-title":"Ann Clin Biochem"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102970_b0390","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10549-024-07364-0","article-title":"Measuring serum oestrogen levels in breast cancer survivors using vaginal oestrogens: a systematic review","volume":"206","author":"Pearson","year":"2024","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102970_b0395","first-page":"52","article-title":"Recommendations for the measurement of sexual steroids in clinical practice. A position statement of SEQC(ML)\/SEEN\/SEEP","volume":"4","author":"Casals","year":"2023","journal-title":"Adv Lab Med"},{"key":"10.1016\/j.ctrv.2025.102970_b0400","article-title":"Detection and characterization of estradiol (E2) and unconjugated estriol (uE3) immunoassay interference due to anti-bovine alkaline phosphatase (ALP) antibodies","volume":"17","author":"Maharjan","year":"2019","journal-title":"Pract Lab Med"},{"issue":"1","key":"10.1016\/j.ctrv.2025.102970_b0405","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12905-022-01828-5","article-title":"Falsely elevated serum estradiol in woman of reproductive age led to unnecessary intervention and delayed fertility opportunity: a case report and literature review","volume":"22","author":"Zhang","year":"2022","journal-title":"BMC Womens Health"},{"issue":"7","key":"10.1016\/j.ctrv.2025.102970_b0410","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.111672","article-title":"Estrone, the major postmenopausal estrogen, binds ERa to induce SNAI2, epithelial-to-mesenchymal transition, and ER+ breast cancer metastasis","volume":"41","author":"Qureshi","year":"2022","journal-title":"Cell Rep"},{"issue":"3","key":"10.1016\/j.ctrv.2025.102970_b0415","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1093\/humupd\/dmac045","article-title":"Anti-M\u00fcllerian hormone for the diagnosis and prediction of menopause: a systematic review","volume":"29","author":"Nelson","year":"2023","journal-title":"Hum Reprod Update"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2025.102970_b0420","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.505","volume":"42","author":"Kalinsky","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.102970_b0425","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3389\/fendo.2017.00110","article-title":"Gonadotropin-releasing hormone and its role in the enteric nervous system","volume":"8","author":"Ohlsson","year":"2017","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102970_b0430","doi-asserted-by":"crossref","first-page":"e551","DOI":"10.1016\/j.clbc.2020.05.011","article-title":"Oral GnRH antagonist ovarian suppression after escape from GnRH agonist in breast cancer patients","volume":"20","author":"Coyne","year":"2020","journal-title":"Clin Breast Cancer"},{"issue":"17","key":"10.1016\/j.ctrv.2025.102970_b0435","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1007\/s40265-018-1014-3","article-title":"Elagolix: first global approval","volume":"78","author":"Lamb","year":"2018","journal-title":"Drugs"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102970_b0440","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2217\/cer-2018-0124","article-title":"Cost\u2013effectiveness of elagolix versus leuprolide acetate for treating moderate-to-severe endometriosis pain in the USA","volume":"8","author":"Wang","year":"2019","journal-title":"J Comp Eff Res"},{"key":"10.1016\/j.ctrv.2025.102970_b0445","article-title":"Degarelix for treating advanced hormone-sensitive prostate cancer","volume":"8(8)","author":"Zengerling","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.ctrv.2025.102970_b0450","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.actbio.2015.02.022","article-title":"Targeted delivery of cisplatin by LHRH-peptide conjugated dextran nanoparticles suppresses breast cancer growth and metastasis","volume":"18","author":"Li","year":"2015","journal-title":"Acta Biomater"},{"issue":"1\u20132","key":"10.1016\/j.ctrv.2025.102970_b0455","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.ijpharm.2012.04.033","article-title":"The in vivo antitumor activity of LHRH targeted methotrexate-human serum albumin nanoparticles in 4T1 tumor-bearing Balb\/c mice","volume":"431","author":"Taheri","year":"2012","journal-title":"Int J Pharm"},{"key":"10.1016\/j.ctrv.2025.102970_b0460","first-page":"697","article-title":"Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes","volume":"5","author":"He","year":"2010","journal-title":"Int J Nanomed."},{"key":"10.1016\/j.ctrv.2025.102970_b0465","first-page":"401","article-title":"Functionalized liposomes for targeted breast cancer drug delivery","volume":"24","author":"Nel","year":"2023","journal-title":"Bioact Mater"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102970_b0470","doi-asserted-by":"crossref","DOI":"10.1016\/j.urology.2005.11.015","article-title":"Failure of gonadotropin-releasing hormone agonists with and without sterile abscess formation at depot sites: insight into mechanisms?","volume":"67","author":"Daskivich","year":"2006","journal-title":"Urology"},{"issue":"1\u20132","key":"10.1016\/j.ctrv.2025.102970_b0475","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.mce.2013.09.029","article-title":"PACAP modulates GnRH signaling in gonadotropes","volume":"385","author":"Halvorson","year":"2014","journal-title":"Mol Cell Endocrinol"},{"issue":"14","key":"10.1016\/j.ctrv.2025.102970_b0480","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1200\/JCO.2015.62.3728","article-title":"Incomplete estrogen suppression with gonadotropin-releasing hormone agonists may reduce clinical efficacy in premenopausal women with early breast cancer","volume":"34","author":"Dowsett","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.102970_b0485","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.breast.2005.08.019","article-title":"The biology of steroid hormones and endocrine treatment of breast cancer","volume":"14","author":"Dowsett","year":"2005","journal-title":"Breast"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102970_b0490","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1002\/j.1939-4640.1994.tb00470.x","article-title":"Follicle-stimulating hormone (FSH) escape during chronic gonadotropin-releasing hormone (GnRH) agonist and testosterone treatment","volume":"15","author":"Bhasin","year":"1994","journal-title":"J Androl"},{"key":"10.1016\/j.ctrv.2025.102970_b0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2019.04.018","article-title":"PACAP induces FSH\u03b2 gene expression via EPAC","volume":"492","author":"Yeh","year":"2019","journal-title":"Mol Cell Endocrinol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102970_b0500","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1210\/me.2006-0253","article-title":"Reciprocal cross talk between gonadotropin-releasing hormone (GnRH) and prostaglandin receptors regulates GnRH receptor expression and differential gonadotropin secretion","volume":"21","author":"Naor","year":"2007","journal-title":"Mol Endocrinol"},{"issue":"Suppl 1","key":"10.1016\/j.ctrv.2025.102970_b0505","doi-asserted-by":"crossref","first-page":"S67","DOI":"10.3747\/co.22.2320","article-title":"Optimal systemic therapy for early breast cancer in women: a clinical practice guideline","volume":"22","author":"Eisen","year":"2015","journal-title":"Curr Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2025.102970_b0510","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1093\/annonc\/mdt149","article-title":"Predictors of recovery of ovarian function during aromatase inhibitor therapy","volume":"24","author":"Henry","year":"2013","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2025.102970_b0515","doi-asserted-by":"crossref","first-page":"e3455","DOI":"10.1210\/clinem\/dgac238","article-title":"Serum follicle-stimulating hormone and 5-year change in adiposity in healthy postmenopausal women","volume":"107","author":"Mattick","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.ctrv.2025.102970_b0520","article-title":"Ovarian ablation as treatment for young women with breast cancer","volume":"16","author":"Davidson","year":"1994","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"5","key":"10.1016\/j.ctrv.2025.102970_b0525","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.breast.2009.09.005","article-title":"Ovarian ablation by radiation therapy: is it still an option for the ablation of ovarian function in endocrine responsive premenopausal breast cancer patients?","volume":"18","author":"Bese","year":"2009","journal-title":"Breast"},{"issue":"2","key":"10.1016\/j.ctrv.2025.102970_b0530","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s10549-021-06368-4","article-title":"Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer","volume":"190","author":"Sukumar","year":"2021","journal-title":"Breast Cancer Res Treat"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225000921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225000921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T06:49:25Z","timestamp":1755499765000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225000921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":105,"alternative-id":["S0305737225000921"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102970","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ovarian escape in premenopausal breast cancer: Challenges and strategies for optimizing hormone suppression","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.102970","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102970"}}